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INTRODUCTION
Although knowing much about the neuronal life and death, 
we remain unsure of their exact molecular nature. As often oc-
curs, the framework of an initial concept of the physiological 
role of a newly discovered molecules extends in the light of 
emerging findings. This is also the case with the neurotrophin 
brain-derived neurotrophic factor (BDNF) and the neurotrans-
mitter glutamate. Recent data suggests that the protein family 
of the neurotrophins, consisting of nerve growth factor (NGF), 
BDNF and neurotrophin-3, -4/5, and -6, might act as ‘neuro-
transmitters’ exerting modulating effects on synaptic structure 
and function, while glutamate might have ‘trophic’ effects in 
neurons. Though neurotransmitters and neurotrophins have 
overlapping functions in vivo, they operate in concert to finely 
tune the neuronal physiology as reviewed in the state-of-the-
science article by Georgiev and colleagues (1).
BDNF
Neurotrophins, particularly, NGF and BDNF are now well 
recognized to mediate a dizzying number of effects, ranging 
from the Rita Levi-Montalcini’s neurotrophic (2) through im-
munotrophic (3) to metabotrophic (4) and synaptotrophic (5) 
effects. There is a compelling evidence indicating that in ad-
dition to their actions on neuronal differentiation and survival, 
BDNF and its receptor tropomyosin-related receptor kinase 
B (TrkB) are uniquely important for the process of activity-
dependent synaptic plasticity including long-term potentia-
And so these men of Indostan
Disputed loud and long,
Each in his own opinion
Exceeding stiff and strong,
Though each was partly in the right,
And all were in the wrong!
John Godfrey Saxe (1816-1887)
E d i t o r i a l
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tion, long-term depression, and dendritic spine density and 
cytoskeletal dynamics, underlying various cognitive functions 
such as learning and memory encoding and storage (6-9). Lo-
calization of BDNF and TrkB receptor to glutamate synapses 
makes this system intriguing as a dynamic, activity-dependent 
regulator of excitatory transmission that is implicated in the 
mechanisms of memory storage and mood control (10-12) as 
well as neuropsychiatric diseases (13-15). 
BDNF-NMDAR CROSSTALK
The influx of Ca2+ through ionotropic glutamate receptor 
channels is thought to contribute to synaptic function, and 
when this influx is in excess, it results in the loss of neurons 
associated with a number of brain disorders. Georgiev and 
colleagues (1) focused their review on the multiple cross-
talk possibilities between BDNF and N-methyl-D-aspartate 
receptor (NMDAR) prosurvival signaling pathways, both 
of which utilize Ca2+, calmodulin/CaMK, Ras, PI3/Akt and 
ERK-1/2 as messengers. A caveat however is necessary - the 
intraneuronal space is far from being disorganized chemical 
solution of electrolytes, neurotransmitters and enzymes, so 
that each cascade in vivo is highly organized and localized 
to nanosized subplasmalemmal domains (typically) under 
lipid raft, structurally stabilized by various (and in most cases 
unknown yet) scaffold proteins. This is the case of synaptic 
versus extrasynaptic NMDAR signaling, the former exert-
ing prosurvival effect upon neurons, while the latter triggers 
prosurvival-“shut off” pathways. The mystery seems to be 
intractable by the older hypothesis according to which ex-
trasynaptic receptors are composed of different subunits (16) 
since in immature neurons both synaptic and extrasynaptic 
NMDARs are composed of NR1/NR2B assemblies (17). 
The puzzle was recently solved by proving experimentally 
the existence of nanodomains: NMDAR-mediated ERK-
1/2 activation requires a specific coupling of NMDAR, Src 
and ERK, via caveolin-1, which helps the assembly of the 
signaling cascade within the neuronal lipid rafts (18). The 
crosstalk between synaptic and extrasynaptic NMDARs is 
thus precluded by the nanodomain organization of the in-
traneuronal space and neuronal plasmalemma, while synaptic 
NMDAR/TrkB crosstalk is made possible due to formation 
of macromolecular protein-protein assembly composed of 
TrkB, Fyn kinase and NR2B NMDAR (19).
AMPA-TYPE GULATAMATE RECEPTORS (AMPAR)
Until 20 years ago, the NMDAR was the only glutamate recep-
tor known to be Ca2+-permeable. It is now well established that 
the ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid receptors (AMPAR) of glutamate (and structur-
ally related kainate receptors) are densely distributed in the 
mammalian brain and are primarily involved in mediating 
fast excitatory synaptic transmission (20-22). The AMPAR 
can be phosphorylated on their subunits (GluR1, GluR2, and 
GluR4), several key protein kinases, such as protein kinase A, 
protein kinase C, Ca2+/calmodulin-dependent protein kinase 
II, and also TrkB receptor being involved in this phosphoryla-
tion. Further, a family of transmembrane AMPAR regulatory 
proteins (TARPs) profoundly affects the trafficking and gating 
of AMPARs (23). 
AMPARs are tetrameric assemblies of GluR1-4 subunits, 
which form predominantly Na+-permeable ion channels. A 
notable exception is the GluR2 subunit containing AMPARs, 
which might be permeable for Ca2+, depending on the Q/R 
site editing. In adult neurons GluR2 gene encoded glutamine 
(Q) codon in the channel-forming intramembrane segment 
is changed to an arginine (R) codon, which results in Ca2+-
impermeable AMPARs (24). 
BDNF-AMPAR CROSSTALK
Notably, neuronal depolarization induced via small doses 
of AMPAR agonists known as ampakines has been shown 
to markedly raise the BDNF expression levels and lead to 
cognitive enhancement (25-31). At present, there is no much 
data on the biochemical cascades following AMPAR activa-
tion, which are to explain the increased BDNF expression, 
though main players after the AMPAR-mediated depolariza-
tion are L-type voltage-gated calcium channels (VGCCs) 
and AMPAR-associated Lyn kinase, which is activated by 
phosphorylation at Tyr507 and NMDARs. Not surprisingly, the 
signal further utilizes the PI3K/Akt and ERK-1/2 highways 
to promote BDNF gene expression (32). It has been also 
shown that AMPAR-mediated activation of L-type VGCCs 
leads to subsequent BDNF release that has trophic effect 
upon GABAergic synapses in the newborn rat hippocampus 
(33). Conversely, though BDNF seems to have no fast effect 
on modulating synaptic AMPAR currents (34), BDNF/TrkB 
signaling enhances mRNAGluR1-4 expression (35,36), triggers 
local translation of mRNAGluR1 under dendritic spines (12) 
and regulates the AMPAR trafficking to postsynaptic densities 
(37). Noteworthy, BDNF enhances tyrosine phosphorylation 
of the AMPAR subunit GluR1 via NMDA receptor-dependent 
mechanisms (38).
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BLIND MAN-ELEPHANT CROSSTALK
In a 19th century poem by John Godfrey Saxe (39) based on 
Indian parable, six blind men touch an elephant to learn what 
it is like. Each one touches a different, but only one part, ob-
taining varying views depending upon one’s perspective. Like 
the elephant to blind men, the glutamatergic singnaling ma-
chinery has different components to be analyzed. To conceive 
its entirety, further multidisciplinary research is required - it 
may hopefully provide us with a better understanding of the 
emerging roles BDNF-NMDAR and BDNF-AMPAR signal-
ing pathways play in neuronal health and disease. Moreover, 
they may represent potential therapeutic targets that will allow 
us to holistically see the picture rather than just individual 
parts. For example, several evidences show impaired syn-
aptic plasticity of glutamatergic synapses in diseases where 
compromised BDNF function has been observed, such as 
Huntington’s disease, Alzheimer’s disease, depression and Rett 
syndrome (13-15,28,30), suggesting that BDNF-AMPAR and 
BDNF-NMDAR crosstalks may be therapeutically relevant. 
Noteworthy, transactivation of Trk receptors by G protein-
coupled receptor ligands has recently emerged as a novel 
biology of neurotrophin actions (40-42, for BDNF-serotonin 
tandem, see 43). Whether these molecules may be involved 
in BDNF-NMDAR and/or BDNF-AMPAR crosstalk remains 
to be elucidated. 
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